The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Outcome of Preventive Surgery and Screening for Breast and Ovarian Cancer in BRCA Mutation Carriers
Abstract
PURPOSE: To prospectively determine the impact of genetic counseling and testing on risk-reduction strategies and cancer incidence in a cohort of individuals at hereditary risk for breast and ovarian cancer. PATIENTS AND METHODS: Two hundred fifty-one individuals with BRCA mutations were identified at a single comprehensive cancer center from May 1, 1995, through October 31, 2000. Uniform recommendations regarding screening and preventive surgery were provided in the context of genetic counseling. Patients were followed for a mean of 24.8 months (range, 1.6 to 66.0 months) using standardized questionnaires, chart reviews, and contact with primary physicians. RESULTS: Frequency of cancer surveillance by physical examinations and imaging studies increased after genetic counseling and testing. Twenty-one breast, ovarian, primary peritoneal, or fallopian tube cancers were detected after receipt of genetic test results. Among 29 individuals choosing risk-reducing mastectomy after testing, two were found to have occult intraductal breast cancers. Among 90 individuals who underwent risk-reducing salpingo-oophorectomy, one early-stage ovarian neoplasm and one early-stage fallopian tube neoplasm were found. Radiographic or tumor marker–based screening detected six breast cancers, five of which were stage 0/I, one early-stage primary peritoneal cancer, and three stage I or II ovarian cancers. Six additional breast cancers were detected by physical examination between radiographic screening intervals; four of these six tumors were stage I. No stage III or stage IV malignancies were detected after genetic testing. CONCLUSION: This study provides prospective evidence that genetic counseling and testing increased surveillance and led to risk-reducing operations, which resulted in diagnosis of early-stage tumors in patients with BRCA1 and BRCA2 mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews
Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,281
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Cancer Risks in BRCA2 Mutation Carriers
Breast Cancer Linkage Consortium, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,527
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Kwan, E., Jack, E., Vesprini, D. J., Kuperstein, G., Abrahamson, J. L. A., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318787 · Cited by 986
Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation
Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450301 · Cited by 973
Burke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955
Lakhani, S. R., Jacquemier, J., Sloane, J. P., Gusterson, B. A., Anderson, T. J., van de Vijver, M. J., Farid, L. M., Venter, D., Antoniou, A., Storfer-Isser, A., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.15.1138 · Cited by 707
Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers
Rebbeck, T. R., Levin, A. M., Eisen, A., Snyder, C., Watson, P., Cannon-Albright, L., Isaacs, C., Olopade, O., Garber, J. E., Godwin, A. K., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.17.1475 · Cited by 672
Cited by
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Kriege, M., Brekelmans, C. T. M., Boetes, C., Besnard, P. E., Zonderland, H. M., Obdeijn, I. M., Manoliu, R. A., Kok, T., Peterse, H., Tilanus-Linthorst, M. M. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031759 · Cited by 1,687
Risk-Reducing Salpingo-oophorectomy in Women with a BRCA1 or BRCA2 Mutation
Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M., Hudis, C. A., Ellis, N. A., Boyd, J., Borgen, P. I., Barakat, R. R., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020119 · Cited by 1,251
Self-citationKuhl, C. K., Schrading, S., Leutner, C. C., Morakkabati-Spitz, N., Wardelmann, E., Fimmers, R., Kuhn, W., & Schild, H. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.4960 · Cited by 1,147
American Cancer Society Guidelines for Breast Cancer Screening: Update 2003
Smith, R. A., Saslow, D., Andrews Sawyer, K., Burke, W., Costanza, M. E., Evans, W. P., Foster, R. S., Hendrick, E., Eyre, H. J., & Sener, S. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.3.141 · Cited by 770
Spectrum of Mutations in BRCA1, BRCA2, CHEK2, and TP53 in Families at High Risk of Breast Cancer
Walsh, T., Casadei, S., Coats, K. H., Swisher, E., Stray, S. M., Higgins, J., Roach, K. C., Mandell, J., Lee, M. K., Ciernikova, S., et al. (2006) · JAMA · doi:10.1001/jama.295.12.1379 · Cited by 666
Kauff, N. D., Domchek, S. M., Friebel, T. M., Robson, M. E., Lee, J., Garber, J. E., Isaacs, C., Evans, D. G., Lynch, H., Eeles, R. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9626 · Cited by 589
Self-citationSystematic Review: Using Magnetic Resonance Imaging to Screen Women at High Risk for Breast Cancer
Warner, E., Messersmith, H., Causer, P., Eisen, A., Shumak, R., & Plewes, D. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-9-200805060-00007 · Cited by 564
Kuhl, C., Weigel, S., Schrading, S., Arand, B., Bieling, H., König, R., Tombach, B., Leutner, C., Rieber-Brambs, A., Nordhoff, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.0839 · Cited by 501
Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations
Fackenthal, J. D., & Olopade, O. I. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2054 · Cited by 488
Progress and Challenges in Screening for Early Detection of Ovarian Cancer
Jacobs, I. J., & Menon, U. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r400006-mcp200 · Cited by 458
Powell, C. B., Kenley, E., Chen, L.-M., Crawford, B., McLennan, J., Zaloudek, C., Komaromy, M., Beattie, M., & Ziegler, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.109 · Cited by 372
National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer
Childers, C. P., Childers, K. K., Maggard-Gibbons, M., & Macinko, J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.6314 · Cited by 351
Nelson, H. D., Huffman, L. H., Fu, R., & Harris, E. L. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-5-200509060-00012 · Cited by 346
ACR Appropriateness Criteria Breast Cancer Screening
Mainiero, M. B., Lourenco, A., Mahoney, M. C., Newell, M. S., Bailey, L., Barke, L. D., D'Orsi, C., Harvey, J. A., Hayes, M. K., Huynh, P. T., et al. (2013) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2012.09.036 · Cited by 342
Characterization of BRCA1 and BRCA2 Mutations in a Large United States Sample
Chen, S., Iversen, E. S., Friebel, T., Finkelstein, D., Weber, B. L., Eisen, A., Peterson, L. E., Schildkraut, J. M., Isaacs, C., Peshkin, B. N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6772 · Cited by 317
Robson, M. E., Chappuis, P. O., Satagopan, J., Wong, N., Boyd, J., Goffin, J. R., Hudis, C., Roberge, D., Norton, L., Bégin, L. R., et al. (2003) · Breast Cancer Research · doi:10.1186/bcr658 · Cited by 307
Self-citationDelivery of Genomic Medicine for Common Chronic Adult Diseases: A Systematic Review
Scheuner, M. T., Sieverding, P., & Shekelle, P. G. (2008) · JAMA · doi:10.1001/jama.299.11.1320 · Cited by 305
Warner, E., Hill, K., Causer, P., Plewes, D., Jong, R., Yaffe, M., Foulkes, W. D., Ghadirian, P., Lynch, H., Couch, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0835 · Cited by 280
The "Duty to Warn" a Patient's Family Members About Hereditary Disease Risks
Offit, K. (2004) · JAMA · doi:10.1001/jama.292.12.1469 · Cited by 270
Self-citationManagement of an Inherited Predisposition to Breast Cancer
Robson, M., & Offit, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp071286 · Cited by 252
Self-citationSurgical risk reduction: Prophylactic salpingo-oophorectomy and prophylactic mastectomy
Dowdy, S. C., Stefanek, M., & Hartmann, L. C. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.04.028 · Cited by 61
Risk‐Reduction Surgery Decisions in High‐Risk Women Seen for Genetic Counseling
Ray, J. A., Loescher, L. J., & Brewer, M. (2005) · Journal of Genetic Counseling · doi:10.1007/s10897-005-5833-5 · Cited by 53
Lee, J. M., Kopans, D. B., McMahon, P. M., Halpern, E. F., Ryan, P. D., Weinstein, M. C., & Gazelle, G. S. (2008) · Radiology · doi:10.1148/radiol.2463070224 · Cited by 45
Metadata
- Authors
- Scheuer, L., Kauff, N., Robson, M., Kelly, B., Barakat, R., Satagopan, J., Ellis, N., Hensley, M., Boyd, J., Borgen, P., Norton, L., & Offit, K.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-03-01
- Volume
- 20
- Issue
- 5
- Pages
- 1260-1268
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4241726394
- Cited by
- 239
- References
- 38
- FWCI
- 11.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.